Shares of Bioline RX Ltd (NASDAQ:BLRX) have been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $3.20.
A number of analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Bioline RX in a report on Tuesday, September 26th. Zacks Investment Research raised shares of Bioline RX from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. Maxim Group set a $3.00 target price on shares of Bioline RX and gave the stock a “buy” rating in a report on Monday, December 4th. Oppenheimer set a $3.00 target price on shares of Bioline RX and gave the stock a “buy” rating in a report on Wednesday, October 18th. Finally, ValuEngine cut shares of Bioline RX from a “hold” rating to a “sell” rating in a report on Thursday, August 24th.
Shares of Bioline RX (BLRX) traded up $0.02 during trading hours on Thursday, hitting $1.08. 251,018 shares of the company’s stock were exchanged, compared to its average volume of 486,667. Bioline RX has a 52 week low of $0.80 and a 52 week high of $1.38.
An institutional investor recently bought a new position in Bioline RX stock. Renaissance Technologies LLC purchased a new position in shares of Bioline RX Ltd (NASDAQ:BLRX) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 131,480 shares of the biotechnology company’s stock, valued at approximately $126,000. Renaissance Technologies LLC owned about 0.21% of Bioline RX as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 37.03% of the company’s stock.
WARNING: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/bioline-rx-ltd-blrx-given-average-recommendation-of-hold-by-brokerages.html.
Bioline RX Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.